Information Provided By:
Fly News Breaks for November 21, 2017
AXGN
Nov 21, 2017 | 08:51 EDT
Lake Street analyst Bruce Jackson raised his price target for AxoGen to $26 following yesterday's analyst meeting. The company provided a business update and detailed a new product initiative for reconstructive breast surgery, Jackson tells investors in a research note. The analyst believes pipeline development programs in breast reconstruction and lower limb iatrogenic nerve injury can leverage the company's existing call points and provide some upside to 2018 estimates. He keeps a Buy rating on AxoGen.
News For AXGN From the Last 2 Days
There are no results for your query AXGN
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.